Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., commonly referred to as Accelerate, is a leading innovator in the field of diagnostic solutions, headquartered in the United States. Founded in 2012, the company has rapidly established itself within the medical diagnostics industry, focusing primarily on the development of advanced technologies for the rapid detection of infectious diseases. With a strong presence in major operational regions across North America and Europe, Accelerate's core products, including the Accelerate Pheno™ system, stand out for their ability to deliver precise results in a fraction of the time compared to traditional methods. This unique capability not only enhances patient care but also optimises antibiotic stewardship. Recognised for its commitment to improving clinical outcomes, Accelerate Diagnostics has achieved significant milestones, positioning itself as a key player in the market for rapid diagnostic solutions.
DitchCarbon Score
How does Accelerate Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Accelerate Diagnostics, Inc.'s score of 31 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Accelerate Diagnostics, Inc.'s reported carbon emissions
In 2023, Accelerate Diagnostics, Inc. reported significant carbon emissions, totalling approximately 113,528,000 kg CO2e for Scope 1, 139,701,000 kg CO2e for Scope 2, and a staggering 6,800,000,000 kg CO2e for Scope 3 emissions. This data highlights the company's substantial carbon footprint, particularly in Scope 3, which encompasses emissions from purchased goods and services, upstream transportation, and product use. To address these emissions, Accelerate Diagnostics has set ambitious reduction targets. By 2030, the company aims to reduce its operational greenhouse gas emissions (Scope 1 and 2) by 42% and Scope 3 emissions by 25%, using 2022 as the baseline year. Furthermore, the company has committed to achieving net zero emissions across all scopes by 2050, demonstrating a long-term commitment to sustainability and climate action. These initiatives reflect the company's recognition of the urgent need to mitigate climate change impacts and align with industry standards for environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | 000,000,000 |
| Scope 2 | - | 000,000,000 |
| Scope 3 | 6,800,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Accelerate Diagnostics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
